Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.

Saved in:
Bibliographic Details
Title: Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.
Authors: Boukhaled GM; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. giselle.boukhaled@uhnresearch.ca., Gadalla R; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Elsaesser HJ; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Abd-Rabbo D; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Quevedo R; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Yang SYC; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Guo M; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.; Department of Immunology, University of Toronto, Toronto, Ontario, Canada., Wang BX; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Noamani B; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Gray D; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Lau SCM; Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada.; Department of Medical Oncology, Perlmutter Cancer Center, NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA., Taylor K; Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada., Aung K; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Spreafico A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada., Hansen AR; Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada., Saibil SD; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Hirano N; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada., Guidos C; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.; Program in Developmental and Stem Cell Biology, Hospital for Sick Children Research Institute, Toronto, Ontario, Canada., Pugh TJ; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., McGaha TL; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.; Department of Immunology, University of Toronto, Toronto, Ontario, Canada., Ohashi PS; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.; Department of Immunology, University of Toronto, Toronto, Ontario, Canada., Sacher AG; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada., Butler MO; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Brooks DG; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. dbrooks@uhnresearch.ca.; Department of Immunology, University of Toronto, Toronto, Ontario, Canada. dbrooks@uhnresearch.ca.
Source: Nature immunology [Nat Immunol] 2022 Aug; Vol. 23 (8), pp. 1273-1283. Date of Electronic Publication: 2022 Jul 14.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Nature America Inc Country of Publication: United States NLM ID: 100941354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-2916 (Electronic) Linking ISSN: 15292908 NLM ISO Abbreviation: Nat Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1529-2916
DOI:10.1038/s41590-022-01262-7